Concordia International is a diverse healthcare company focused on delivering its portfolio of legacy pharmaceutical products and orphan drugs to patients in more than 100 countries.
Concordia International is the result of the acquisition by Concordia Healthcare Corp (now Concordia International Corp) of the AMCo group on 21 October 2015 (see press release here). The combined businesses are highly complementary to each other, supplying well-established product portfolios of niche, complex medicines to patients and healthcare authorities across the world. Concordia is publicly listed on the TSX/Nasdaq stock exchanges and is headquartered in Oakville, Toronto, Canada. We also have offices in the UK, Ireland, Sweden, the UAE, India and Australia. Our medicines make a real difference to the patients and healthcare authorities who rely on them. More information can be found on our Products page.
We have an extensive Environmental, Social & Governance programme [see here]. We believe that our support makes a real difference to those whom we help. These projects resulted in Concordia/AMCo being one of four companies shortlisted for the Global Generics and Biosimilars Awards in October 2015 for CSR initiatives.
In 2015 we were awarded Gold standard by Investors in People for our commitment to our staff and our training programmes. We also take compliance extremely seriously, and in January 2016 we became the first pharma company in the world to achieve British Standards BS 10500 accreditation for our comprehensive compliance management systems.
If you would like to learn more about Concordia International, its products or its people, please contact us